Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
![A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram](https://www.researchgate.net/profile/Richard-Stephens-3/publication/5503862/figure/fig2/AS:667207130423307@1536085984764/A-Overall-survival-OS-in-elderly-patients-70-years-in-relation-to-treatment-arm.png)
A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram
![Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy](https://abstracts.mirrorsmed.org/sites/default/files/908-0.jpg)
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
![Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer](https://eau-bb-01.s3.amazonaws.com/webcasts/EAU22/1313581ca4fd152b6f8cec0b88292a11ae664b/131358/media/Slide1.jpg)
Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer
![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F2.large.jpg)
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5716896/bin/nihms896091f1.jpg)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
![Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12890-020-01270-z/MediaObjects/12890_2020_1270_Fig4_HTML.png)
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene](https://www.spandidos-publications.com/article_images/mco/2/5/MCO-02-05-0731-g02.jpg)
Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS](http://pubs.sciepub.com/jcrt/5/2/3/bigimage/fig1.png)
Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr2.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png)
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
![Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram](https://www.researchgate.net/publication/333294637/figure/fig2/AS:761410896277505@1558545912697/Kaplan-Meier-curve-showing-the-overall-survival-OS-of-the-patient-cohort-grouped-by.png)
Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram
![Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram](https://www.researchgate.net/publication/342628025/figure/fig2/AS:908830661697536@1593693523052/Kaplan-Meier-curves-for-overall-survival-OS-overall-survival-non-MDT-non.png)